9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques

Koen K.A. Van Rompay, Julie M. Cherrington, Marta Marthas, Christopher J. Berardi, Andrew S. Mulato, Abbie Spinner, Ross P. Tarara, Don R. Canfield, Stephan Telm, Norbert Bischofberger, Niels C Pedersen

Research output: Contribution to journalArticlepeer-review

98 Scopus citations


The long-term therapeutic and toxic effects of 9-[2- (phosphonomethoxy)propyl]adenine (PMPA) were evaluated in simian immunodeficiency virus (SIV)-infected newborn rhesus macaques. Four untreated SIV-infected newborn macaques developed persistently high levels of viremia, and three of the four animals had rapidly fatal disease within 3 months. In contrast, long-term PMPA treatment of four newborn macaques starting 3 weeks after virus inoculation resulted in a rapid, pronounced, and persistent reduction of viremia in three of the four animals. Emergence of virus with fivefold-decreased susceptibility to PMPA occurred in all four PMPA-treated animals and was associated with the development of a lysine-to-arginine substitution at amino acid 65 (K65R mutation) and additional mutations in the reverse transcriptase; however, the clinical implications of this low-level drug resistance are unclear. No toxic side effects have been seen, and all PMPA-treated animals have remained disease- free for more than 13 months. Our data suggest that PMPA holds much promise for the treatment of human immunodeficiency virus-infected human infants and adults.

Original languageEnglish (US)
Pages (from-to)2586-2591
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Issue number11
StatePublished - Nov 1996

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of '9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques'. Together they form a unique fingerprint.

Cite this